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of Abdominal Aortic Aneurysm Expansion’’
M. Thompson
St George’s Vascular Institute, Department of Vascular Surgery, 4th Floor St James Wing,
St George’s Hospital NHS Trust, Blackshaw Road, London SW17 0QT, UKIn recent years, the management of patients with
abdominal aortic aneurysms has improved with the
introduction of screening, the advent of endovascular
aneurysm repair and the changing emphasis on the
medical management of patients with arterial disease.
There has been increasing importance placed on basic
science investigations into the cellular and molecular
events that drive the aneurysmal process. However,
many fundamental questions regarding the pathobiol-
ogy of abdominal aortic aneurysms remain unan-
swered. In particular, the molecular processes that
underpin aneurysm expansion and rupture are not
fully defined. Understanding these events will be cru-
cial in designing medical therapy to retard aneurysm
expansion, The promise of pharmacotherapy is partic-
ularly applicable to small aneurysms which may be
diagnosed in screened populations.
Pharmacotherapy for small aneurysms is likely to
become a realistic proposition within the next 5e10
years.1 There is some evidence to suggest that current
medical management with anti-hypertensive agents
and HMG Co-A reductase inhibitors may retard aneu-
rysm expansion,2 and encouraging results with low
dose doxycycline have been reported. In a recent
experimental investigation, Yoshimura et al. demon-
strated aneurysm regression for the first time by inhibi-
tion of a major signalling pathway.3 Pharmacotherapy,
when available, is likely to have some side effects and
targeting patients that will achieve maximum benefit
from this therapy is essential.
One of the key steps in improving management of
abdominal aortic aneurysms is to identify which
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expansion. These patients may then be targeted with
pharmacotherapy or early endovascular surgery.4 At
present, only the initial size of the aneurysm provides
a reliable guide to the likely expansion rate. The iden-
tification of serum factors that might predict expan-
sion rate has been a goal of many investigators in
recent years. The concentration of various factors
within the serum has been reported to be associated
with rapid rates of aneurysm expansion. These factors
have included osteoprotegerin, t-PA, macrophage
migration inhibitory factor, cystatin C and MMP-9.5e9
Interestingly most of these serum factors have been
involved in the inflammatory and proteolytic path-
ways that have been implicated in the matrix degra-
dation that characterises mature aneurysm wall.
In this issue of the journal, Halazun et al. report
a convincing independent association between homo-
cysteine concentrations and the rate of aneurysm
expansion. Of particular note was the finding that
elevation of homocysteine levels doubled the expan-
sion rates of aneurysms exceeding 4 cm in diameter.
Although the study was of relatively small size, there
was a weak correlation between aneurysm expansion
rates and plasma homocysteine. This association is
biologically plausible. Previous reports have revealed
a step wise increase in plasma homocysteine and
aortic diameter in subjects with a normal aortic
diameter,10 and in patients with aneurysms.11 Homo-
cysteine is involved in several inflammatory path-
ways and may well have an effect on the biology of
the aortic wall. The difficulty with interpretation of
this study, as with many others, is whether the associ-
ation is causative. This question will really only be an-
swered by a combination of larger series, experimental
results and possibly genotype-phenotype associations.rved.
396 M. ThompsonNevertheless, the findings reported by Halazun
et al. are a significant contribution to the literature
surrounding plasma markers and aneurysm expansion.
With further larger studies it may be possible to
construct a model that incorporates demographic,
morphological and biochemical factors that predict
the rate of aneurysm expansion. This model would
be invaluable in targeting patients for either aggressive
pharmacotherapy or early aneurysm repair.
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